These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 7831664)

  • 1. Pharmacological properties of CY 216 and of its ACLM and BCLM components in the rabbit.
    Peyrou V; Lormeau JC; Caranobe C; Gabaig AM; Crepon B; Saivin S; Houin G; Sié P; Boneu B
    Thromb Haemost; 1994 Aug; 72(2):268-74. PubMed ID: 7831664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
    Bendetowicz AV; Béguin S; Caplain H; Hemker HC
    Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term persistence of low-molecular-weight material with anti-factor Xa activity contributes to anticoagulant and antithrombotic effects after subcutaneous injection of CY 216 in the rabbit.
    Peyrou V; Lormeau JC; Hérault JP; Boneu B; Herbert JM
    Blood Coagul Fibrinolysis; 1997 Apr; 8(3):175-84. PubMed ID: 9167018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological properties of a low molecular weight butyryl heparin derivative (C4-CY 216) with long lasting effects.
    Saivin S; Petitou M; Lormeau JC; Dupouy D; Sié P; Caranobe C; Houin G; Boneu B
    Thromb Haemost; 1992 Mar; 67(3):346-51. PubMed ID: 1322569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
    Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
    Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma--a study in human volunteers.
    Bendetowicz AV; Kai H; Knebel R; Caplain H; Hemker HC; Lindhout T; Béguin S
    Thromb Haemost; 1994 Nov; 72(5):705-12. PubMed ID: 7900078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216.
    Carrie D; Caranobe C; Saivin S; Houin G; Petitou M; Lormeau JC; Van Boeckel C; Meuleman D; Boneu B
    Blood; 1994 Oct; 84(8):2571-7. PubMed ID: 7919374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities: an experimental study in two models of thrombosis in the rabbit.
    Amar J; Caranobe C; Sie P; Boneu B
    Br J Haematol; 1990 Sep; 76(1):94-100. PubMed ID: 2223652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit.
    Briant L; Caranobe C; Saivin S; Sié P; Bayrou B; Houin G; Boneu B
    Thromb Haemost; 1989 Jun; 61(3):348-53. PubMed ID: 2552603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic properties of an unfractionated heparin butyryl derivative with long-lasting effects.
    Saivin S; Petitou M; Lormeau JC; Dupouy D; Sie P; Caranobe C; Houin G; Boneu B
    J Lab Clin Med; 1992 Feb; 119(2):189-96. PubMed ID: 1740633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of the levels of unfractionated and low-molecular-weight heparins in plasma: their effect on thrombin-mediated feedback reactions in vivo. Preliminary results after subcutaneous injection.
    Hemker HC; Béguin S; Bendetowicz AV; Wielders S
    Haemostasis; 1991; 21(4):258-72. PubMed ID: 1665467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The venous antithrombotic profile of naroparcil in the rabbit.
    Millet J; Theveniaux J; Brown NL
    Thromb Haemost; 1994 Dec; 72(6):874-9. PubMed ID: 7740457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis.
    Diquélou A; Dupouy D; Cariou R; Sakariassen KS; Boneu B; Cadroy Y
    Thromb Haemost; 1995 Nov; 74(5):1286-92. PubMed ID: 8607111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
    Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
    Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can the haemorrhagic component of heparin be identified? Or an attempt at clean thinking on a dirty drug.
    Hemker HC; Béguin S; Kakkar VV
    Haemostasis; 1996; 26(3):117-26. PubMed ID: 8738586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic properties of long lasting butyryl heparin derivatives in the rabbit.
    Saivin S; Caranobe C; Petitou M; Lormeau JC; Houin G; Boneu B
    Thromb Haemost; 1992 May; 67(5):550-5. PubMed ID: 1325682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rational approach to heparins.
    Hemker HC; Béguin S
    Nouv Rev Fr Hematol (1978); 1992; 34(1):5-9. PubMed ID: 1326098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic properties of a low molecular weight dermatan sulfate: comparison with unfractionated dermatan sulfate.
    Dol F; Petitou M; Lormeau JC; Choay J; Caranobe C; Sie P; Saivin S; Houin G; Boneu B
    J Lab Clin Med; 1990 Jan; 115(1):43-51. PubMed ID: 2299256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.